Advanced Renal Cell Cancer Combination ImmunoThErapy Clinical Trial (ARCITECT)

The purpose of this study is to find out if the combination of botensilimab and balstilimab is more effective and safer at treating in clear cell Renal Cell Cancer (ccRCC) [kidney cancer] that has spread to other parts of the body (metastatic) than the standard combination of nivolumab and ipilimumab. The combination of nivolumab and ipilimumab has already been approved by the Food and Drug Administration (FDA) for use in advanced kidney cancer. The combination of balstilimab and botensilimab is investigational and has not been approved by the Food and Drug Administration (FDA).

Are you Eligible? (Inclusion Criteria)

• Must be 18 years old or older - Patient must not have radiotherapy within 2 weeks prior to starting the study treatment - Patient must not have major surgery less than 28 days prior to starting the study treatment